Complete remission of third recurrence of acute myeloid leukemia after treatment with Imatinib (STI-571)

被引:11
|
作者
Schittenhelm, M
Aichele, O
Kröber, SM
Brümmendorf, T
Kanz, L
Denzlinger, C [1 ]
机构
[1] Univ Tubingen, Dept Haematol Oncol, Sch Med, D-72076 Tubingen, Germany
[2] Univ Tubingen, Inst Pathol, D-72076 Tubingen, Germany
关键词
AML; c-kit; CD117; Imatinib; glivec; STI-571;
D O I
10.1080/1042819031000077034
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We report the case of a 76-year old patient with third relapse of AML who was successfully treated with Imatinib. The decision to try Imatinib was guided by bright expression of c-kit on the patient's blasts. Treatment was well tolerated but the dose was reduced for pancytopenia and later stopped completely because of pneumonia. The patient recovered with i.v. antibiotics, antimycotics and s.c. G-CSF. Reevaluation of the bone marrow after the end of treatment demonstrated the absence of malignant blasts. Treatment with Imatinib was started again with the intention to prolong remission duration. During the following months peripheral blood counts stabilized in the normal range indicating that a fourth complete remission has been achieved in this patient. This is the first report demonstrating that Imatinib can induce complete remission in relapsed c-kit positive AML in an elderly patient. Prolonged cytopenia remains a considerable problem indicating that normal haematopoiesis is not completely independent of the signalling cascades inhibited by Imatinib. Nevertheless our report supports further study of this drug in c-kit positive AML.
引用
收藏
页码:1251 / 1253
页数:3
相关论文
共 50 条
  • [1] Gleevec (STI-571) for chronic myeloid leukemia
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2001, 43 (1106): : 49 - 52
  • [2] Complete remission after administration of the c-kit inhibitor STI-571 (Gleevec™) in a patient with acute myeloid leukemia refractory to chemotherapy.
    Fischer, T
    Gamm, H
    Beck, J
    Gschaidmeier, H
    Theobald, M
    Christoph, H
    BLOOD, 2001, 98 (11) : 588A - 588A
  • [3] Treatment of residual disease in chronic myeloid leukemia with STI-571 (Glivec)
    Geissler, K
    Agis, H
    Sagaster, V
    ACTA MEDICA AUSTRIACA, 2002, 29 : 66 - 68
  • [4] Imatinib (STI-571) for treatment of relapse after stem cell transplantation (SCT).
    Miller, CB
    Smith, BD
    Gore, SD
    Dolan, S
    Yerian, JA
    Hartley, EE
    Koehler, J
    Topolsky, D
    O'Donnell, P
    Jones, RJ
    BLOOD, 2001, 98 (11) : 400A - 401A
  • [5] STI-571 (Gleevec) in the treatment of chronic myeloid leukaemia
    Kumar, L
    NATIONAL MEDICAL JOURNAL OF INDIA, 2002, 15 (05): : 298 - 298
  • [6] Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era
    Wu, PC
    Langerman, A
    Ryan, CW
    Hart, J
    Swiger, S
    Posner, MC
    SURGERY, 2003, 134 (04) : 656 - 665
  • [7] Rapid and complete response to imatinib mesylate (STI-571) in a patient with idiopathic hypereosinophilia.
    Nolasco, I
    Carvalho, S
    Parreira, A
    BLOOD, 2002, 100 (11) : 346B - 347B
  • [8] Skin reactions to imatinib mesylate (STI-571) in patients with chronic myeloid leukemia (CML): Clinical features and histopathology.
    Stone, R
    Galinsky, I
    Haynes, H
    Soiffer, R
    Alyea, E
    Neuberg, D
    Tawa, M
    Antin, J
    Resta, D
    Granter, S
    DeAngelo, D
    BLOOD, 2001, 98 (11) : 141A - 141A
  • [9] Potential Role of Imatinib Mesylate (Gleevec, STI-571) in the Treatment of Vestibular Schwannoma
    Altuna, Xabier
    Lopez, Jay Patrick
    Yu, Michael Andrew
    Arandazi, Maria Jesus
    Harris, Jeffrey P.
    Wang-Rodriguez, Jessica
    An, Yi
    Dobrow, Robert
    Doherty, Joni K.
    Ongkeko, Weg M.
    OTOLOGY & NEUROTOLOGY, 2011, 32 (01) : 163 - 170
  • [10] Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era - Discussion
    Aranha, GV
    Tallamonti, MS
    Onders, RP
    Pollak, R
    Posner
    SURGERY, 2003, 134 (04) : 665 - 666